The director of the Ann Kimball and John W. Johnson Center for Cellular Therapeutics at Houston Methodist Hospital discussed the clinical manifestations of frontotemporal dementia (FTD) and how Coya Therapeutics is moving toward precision medicine with their FTD candidate, COYA 301. [WATCH TIME: 4 minutes]
Representatives from the SCN8A Alliance discussed ways to improve the quality of life for children with SCN8A-related epilepsy, highlighting the critical role of early genetic diagnosis and targeted interventions. [WATCH TIME: 4 minutes]
The professor of neurology at University of Rochester discussed a new model on how Parkinson disease may originate, highlighting potential environmental causes and progression. [WATCH TIME: 5 minutes]
The senior vice president of research at The ALS Association discussed the need for standardizing ALS diagnosis across institutions to reduce delays and ensure timely treatment. [WATCH TIME: 4 minutes]
SEEG has transformed the surgical investigation of refractory epilepsy, enabling clinicians to map complex seizure networks with precision, leading to more targeted treatment options for patients.
The pediatric neurologist and epileptologist at the University of Michigan's Mott Children's Hospital spoke at the 2022 AES conference about disparities that currently exist in epilepsy care. [WATCH TIME: 4 minutes]
The chief medical officer at Avidity Biosciences talked about how its exon skipping AOC therapies are designed to address the lack of functional dystrophin protein among patients with Duchenne muscular dystrophy to improve muscle function. [WATCH TIME: 4 minutes]
The research scientist from the University of Texas Medical School discussed some of the challenges and opportunities that machine learning presents in patient care.
The director of academic clinical research at Orlando Health reflected on the journey of a blood test for traumatic brain injury to clinical use, highlighting the collaborative efforts and patient participation that made it possible. [WATCH TIME: 3 minutes]
The associate professor of biology at Georgetown University talked about how immune cells can communicate with brain cells to enhance repair processes, which may offer potential treatment targets for multiple sclerosis. [WATCH TIME: 5 minutes]
The professor of neurology at UMass Chan School of Medicine discussed the various impacts Daylight Savings Time has on sleep quality and overall health in children and adolescents. [WATCH TIME: 3 minutes]
The division chief of vascular neurology at the University of Utah discussed the individual role that clinicians and neurologists can play to increase interest in the field of neurology. [WATCH TIME: 2 minutes]
The Meta A. Neumann Professor of Neurology at George Washington University provided an overview of a new phase 3 study testing the efficacy and safety of cladribine versus placebo in generalized myasthenia gravis. [WATCH TIME: 3 minutes]
The assistant professor of neurology at the Keck School of Medicine at University of Southern California discussed the importance of having additional agents to treat Parkinson disease.
The neurologist at Cleveland Clinic’s Lou Ruvo Center for Brain Health detailed new findings on whether initial cognitive symptoms have similar rates of functional decline across a handful of neurodegenerative disorders. [WATCH TIME: 3 minutes]
The neuropsychologist and assistant professor of neurology at the University of California, San Francisco Memory and Aging Center provided comment on her presentation from AAN 2024 examining the association of area deprivation index with cognitive functioning in Black women. [WATCH TIME: 3 minutes]
The director of the Dartmouth Epilepsy Program provided an overview of some of the critical unmet needs within ongoing epilepsy research following the recent AES Annual Meeting.
Nina Miolane, PhD, and Amy Kuceyeski, PhD, the codirectors of the Ann S. Bowers Women's Brain Health Initiative AI Core, provided their commentary on the challenges and progress made in women’s neurology.
Sucheta M. Joshi, MD, MS, FAES, FAAP, and Nicholas Beimer, MD, discussed the reasons why EpiTRAQ may influence earlier discussions with patients prior to the epilepsy transition process.
A trio of experts talked about Lexeo Therapeutics’ LX1001 gene therapy trial that demonstrated promising safety and biomarker effects in patients with early-stage Alzheimer disease. [WATCH TIME: 5 minutes]
The clinical professor of neurology at Stanford University School of Medicine talked about the collaboration of Rapport leveraging NeuroPace’s data analysis capabilities to study the target delivery of a therapy for focal epilepsy. [WATCH TIME: 5 minutes]
The neurologist at University of Utah discussed the potential of using teleneurology to diagnose neurological conditions.
The senior VP of clinical research at Eisai discussed findings from a phase 2 study assessing irsenontrine in patients with dementia with Lewy bodies and Parkinson disease dementia. [WATCH TIME: 4 minutes]
Mindy K. Bixby, DO and Laxman Bahroo, DO give key advice to community neurologists and emphasize the importance of effective communication between patients and providers.
Episode 7 of the AUPN Leadership Minute features Donald S. Higgins Jr., MD, of the VHA; and Justin C. McArthur, MBBS, MPH, of Johns Hopkins University. [WATCH TIME: 4 minutes]
The associate professor of neurochemistry at the University of Gothenburg in Sweden talked about a pilot study that explored the potential of finger prick tests to remotely collect blood and provide reliable biomarker results for Alzheimer disease diagnosis. [WATCH TIME: 5 minutes]
The professor of neurology at the University of Alabama at Birmingham Epilepsy Center provided comment on raising awareness for infantile spasms, especially during Infantile Spams Awareness Week, which is celebrated the first week of December. [WATCH TIME: 3 minutes]
The professor of pediatrics at Case Western University discussed the complexities and negative effects for children drastically change their sleep schedules as school begins. [WATCH TIME: 3 minutes]
There should be a holistic approach to how the systems in place affect equity: how medicine is practiced and research is conducted, the structure of academic institutions, and how media influence our perceptions of neurologic conditions.
The kinase inhibitor was approved for patients with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.